Australia markets closed

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
89.81-0.26 (-0.29%)
As of 10:22AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 17.09B
Enterprise value 17.12B
Trailing P/E 103.54
Forward P/E 33.56
PEG ratio (5-yr expected) 0.74
Price/sales (ttm)7.13
Price/book (mrq)3.45
Enterprise value/revenue 7.08
Enterprise value/EBITDA 55.27

Trading information

Stock price history

Beta (5Y monthly) 0.32
52-week change 3-7.63%
S&P500 52-week change 321.23%
52-week high 399.56
52-week low 376.02
50-day moving average 387.64
200-day moving average 389.01

Share statistics

Avg vol (3-month) 31.4M
Avg vol (10-day) 31.57M
Shares outstanding 5189.78M
Implied shares outstanding 6189.78M
Float 8187.23M
% held by insiders 10.84%
% held by institutions 1100.78%
Shares short (28 Mar 2024) 43.06M
Short ratio (28 Mar 2024) 42.39
Short % of float (28 Mar 2024) 41.63%
Short % of shares outstanding (28 Mar 2024) 41.62%
Shares short (prior month 29 Feb 2024) 43.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 6.93%
Operating margin (ttm)4.37%

Management effectiveness

Return on assets (ttm)1.63%
Return on equity (ttm)3.51%

Income statement

Revenue (ttm)2.42B
Revenue per share (ttm)12.88
Quarterly revenue growth (yoy)20.20%
Gross profit (ttm)N/A
EBITDA 276.48M
Net income avi to common (ttm)167.64M
Diluted EPS (ttm)0.87
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.07B
Total cash per share (mrq)5.69
Total debt (mrq)1.13B
Total debt/equity (mrq)22.90%
Current ratio (mrq)2.51
Book value per share (mrq)26.25

Cash flow statement

Operating cash flow (ttm)159.26M
Levered free cash flow (ttm)-25.9M